Comparing Amylyx Pharmaceuticals (NASDAQ:AMLX) & Corbus Pharmaceuticals (NASDAQ:CRBP)

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, analyst recommendations and valuation.

Volatility & Risk

Amylyx Pharmaceuticals has a beta of -0.11, suggesting that its stock price is 111% less volatile than the S&P 500. Comparatively, Corbus Pharmaceuticals has a beta of 2.68, suggesting that its stock price is 168% more volatile than the S&P 500.

Profitability

This table compares Amylyx Pharmaceuticals and Corbus Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%

Institutional and Insider Ownership

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 12.3% of Amylyx Pharmaceuticals shares are owned by insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Amylyx Pharmaceuticals and Corbus Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1	2	9	1	2.77
Corbus Pharmaceuticals	2	0	8	1	2.73

Amylyx Pharmaceuticals currently has a consensus target price of $23.00, suggesting a potential upside of 67.39%. Corbus Pharmaceuticals has a consensus target price of $42.33, suggesting a potential upside of 264.79%. Given Corbus Pharmaceuticals’ higher possible upside, analysts clearly believe Corbus Pharmaceuticals is more favorable than Amylyx Pharmaceuticals.

Valuation and Earnings

This table compares Amylyx Pharmaceuticals and Corbus Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37 million	17.49	-$144.74 million	($1.50)	-9.16
Corbus Pharmaceuticals	N/A	N/A	-$78.54 million	($5.82)	-1.99

Corbus Pharmaceuticals has lower revenue, but higher earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Amylyx Pharmaceuticals beats Corbus Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.